Key Points
- GRAIL CFO Aaron Freidin sold 23,619 shares at an average price of $146.39, generating approximately $3.46 million. His remaining direct ownership fell 9.49% to 225,364 shares.
- GRAIL shares opened at $132.90, with a market capitalization of about $5.94 billion and a 52-week range of $41.50 to $166.48. The company remains unprofitable but recently beat quarterly EPS and revenue expectations.
- Analyst sentiment is mixed, with five Buy, six Hold and one Sell rating, resulting in a consensus Hold rating and a $102.70 price target, despite recent price-target increases from several firms.
GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) insider Andrew Partridge sold 7,873 shares of the business's stock in a transaction on Monday, October 5th. The shares were sold at an average price of $146.39, for a total value of $1,152,528.47. Following the completion of the sale, the insider owned 155,865 shares in the company, valued at $22,817,077.35. This represents a 4.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.
GRAIL Trading Down 3.2%
GRAL opened at $132.90 on Thursday. The stock's 50-day moving average price is $89.70 and its 200 day moving average price is $70.98. GRAIL, Inc. has a 12-month low of $41.50 and a 12-month high of $166.48. The firm has a market cap of $5.94 billion, a price-to-earnings ratio of -13.63 and a beta of 2.83.
GRAIL (NASDAQ:GRAL - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share for the quarter, beating the consensus estimate of ($2.66) by $0.10. The company had revenue of $44.69 million during the quarter, compared to the consensus estimate of $42.39 million. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%. On average, research analysts forecast that GRAIL, Inc. will post -10.41 earnings per share for the current year.
Institutional Investors Weigh In On GRAIL
Large investors have recently modified their holdings of the company. BlackRock Inc. raised its holdings in shares of GRAIL by 20.5% in the 2nd quarter. BlackRock Inc. now owns 3,577,075 shares of the company's stock valued at $244,207,000 after purchasing an additional 608,539 shares in the last quarter. Baker BROS. Advisors LP grew its stake in shares of GRAIL by 27.9% during the fourth quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company's stock worth $178,484,000 after purchasing an additional 455,208 shares in the last quarter. State Street Corp grew its stake in shares of GRAIL by 26.1% during the second quarter. State Street Corp now owns 2,385,514 shares of the company's stock worth $162,859,000 after purchasing an additional 493,621 shares in the last quarter. Primecap Management Co. CA purchased a new position in GRAIL in the second quarter valued at $148,836,000. Finally, Geode Capital Management LLC raised its stake in GRAIL by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 801,503 shares of the company's stock valued at $68,609,000 after buying an additional 71,253 shares in the last quarter.
Analysts Set New Price Targets
A number of research analysts recently weighed in on the stock. UBS Group lifted their price objective on shares of GRAIL from $105.00 to $175.00 and gave the company a "buy" rating in a report on Friday, October 2nd. Mizuho raised their price target on shares of GRAIL from $65.00 to $100.00 and gave the company a "neutral" rating in a research report on Friday, September 25th. Robert W. Baird boosted their price target on shares of GRAIL from $96.00 to $118.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 22nd. Guggenheim lifted their target price on GRAIL from $75.00 to $155.00 and gave the company a "buy" rating in a report on Thursday, October 1st. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of GRAIL in a research note on Friday, July 17th. Five analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, GRAIL presently has a consensus rating of "Hold" and an average price target of $102.70.
Get Our Latest Report on GRAIL
About GRAIL
(
Get Free Report)
GRAIL, Inc is a healthcare company focused on developing blood-based technologies for the early detection of cancer. Its goal is to identify cancer signals before symptoms appear, when treatment may be more effective, by applying genomics, machine learning and other analytical methods to blood samples.
The company's primary product is the Galleri multi-cancer early detection test, a prescription laboratory-developed test designed to screen for signals associated with multiple types of cancer from a single blood draw.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
